Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.

Revenue
+37,272.4%
EPS
+85.0%
Free cash flow
−0.52%
Total debt
+0.22%

Quarter to September 2026, against a year earlier

10.60 0.73 +7.40%
Market cap
$275.7M
P/E
0.0×
Fwd P/E
−2.9×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
ROE
(112.69%) (132.91%) (69.52%) (61.52%)

+8 more TTM periods

Piotroski F-Score
— — 2 1
ROA
(36.04%) (44.91%) (32.50%) (31.45%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(48.74%) (61.77%) (42.69%) (41.10%)
Average Days of Receivables
— — 32.39 0.00
Free Cash Flow per Share
(1.91) (2.02) (2.40) (5.18)
Free Cash Flow
(52.40) (52.32) (59.16) (66.48)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026